Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2014 by University of Nebraska
Incyte Corporation
Information provided by (Responsible Party):
Julie M Vose, MD, University of Nebraska Identifier:
First received: September 5, 2011
Last updated: December 2, 2014
Last verified: December 2014
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: August 2025
  Estimated Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)